Derek Archila
Stock Analyst at Wells Fargo
(3.65)
# 741
Out of 4,884 analysts
179
Total ratings
45.69%
Success rate
7.54%
Average return
Main Sectors:
Stocks Rated by Derek Archila
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KYMR Kymera Therapeutics | Maintains: Overweight | $57 → $53 | $44.79 | +18.33% | 8 | Jun 26, 2025 | |
| ATYR aTyr Pharma | Maintains: Overweight | $17 → $25 | $5.31 | +370.81% | 2 | Jun 20, 2025 | |
| BPMC Blueprint Medicines | Downgrades: Equal-Weight | $143 → $129 | $128.35 | +0.51% | 9 | Jun 17, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Equal-Weight | $26 → $29 | $18.26 | +58.82% | 12 | Jun 2, 2025 | |
| SEPN Septerna | Maintains: Equal-Weight | $11 → $18 | $11.37 | +58.31% | 4 | May 16, 2025 | |
| ARVN Arvinas | Maintains: Overweight | $26 → $19 | $7.95 | +138.99% | 6 | May 2, 2025 | |
| INCY Incyte | Maintains: Equal-Weight | $58 → $59 | $68.45 | -13.81% | 7 | Apr 30, 2025 | |
| NRIX Nurix Therapeutics | Maintains: Overweight | $32 → $25 | $12.73 | +96.39% | 5 | Apr 9, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Overweight | $80 → $91 | $65.77 | +38.36% | 5 | Apr 7, 2025 | |
| CABA Cabaletta Bio | Maintains: Equal-Weight | $6 → $3 | $1.63 | +84.05% | 10 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $10 | $4.87 | +105.34% | 5 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $15 | $1.44 | +941.67% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $723 → $741 | $543.48 | +36.34% | 11 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $36 | $46.15 | -21.99% | 3 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $51 | $23.75 | +114.74% | 3 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $8 → $6 | $1.26 | +376.19% | 4 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $12 → $14 | $13.04 | +7.36% | 5 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $9 | $4.58 | +96.51% | 11 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $47 → $45 | $16.95 | +165.49% | 9 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $8 → $12 | $1.48 | +710.81% | 5 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $27 | $15.67 | +72.30% | 1 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $44 → $24 | $2.81 | +754.09% | 1 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $264 → $289 | $174.18 | +65.92% | 13 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $11 | $2.08 | +428.85% | 4 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $35 → $37 | $22.00 | +68.18% | 3 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $10 | $2.89 | +246.02% | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $37 → $20 | $1.17 | +1,609.40% | 7 | May 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $3.01 | +498.01% | 1 | Aug 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $3.87 | - | 1 | Jul 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $298 → $193 | $28.83 | +569.44% | 1 | Jul 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $61 → $41 | $82.14 | -50.09% | 1 | Apr 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $480 → $160 | $16.73 | +856.37% | 3 | Mar 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $180 → $60 | $11.60 | +417.24% | 3 | Mar 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | $29 | $4.97 | +483.50% | 4 | Dec 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $50 | $2.20 | +2,172.73% | 2 | Jun 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $51 | $13.58 | +275.55% | 1 | Nov 15, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $88 | $27.20 | +223.53% | 1 | Sep 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $23.22 | - | 1 | Sep 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $17.01 | - | 2 | Aug 3, 2017 |
Kymera Therapeutics
Jun 26, 2025
Maintains: Overweight
Price Target: $57 → $53
Current: $44.79
Upside: +18.33%
aTyr Pharma
Jun 20, 2025
Maintains: Overweight
Price Target: $17 → $25
Current: $5.31
Upside: +370.81%
Blueprint Medicines
Jun 17, 2025
Downgrades: Equal-Weight
Price Target: $143 → $129
Current: $128.35
Upside: +0.51%
Apellis Pharmaceuticals
Jun 2, 2025
Maintains: Equal-Weight
Price Target: $26 → $29
Current: $18.26
Upside: +58.82%
Septerna
May 16, 2025
Maintains: Equal-Weight
Price Target: $11 → $18
Current: $11.37
Upside: +58.31%
Arvinas
May 2, 2025
Maintains: Overweight
Price Target: $26 → $19
Current: $7.95
Upside: +138.99%
Incyte
Apr 30, 2025
Maintains: Equal-Weight
Price Target: $58 → $59
Current: $68.45
Upside: -13.81%
Nurix Therapeutics
Apr 9, 2025
Maintains: Overweight
Price Target: $32 → $25
Current: $12.73
Upside: +96.39%
Rhythm Pharmaceuticals
Apr 7, 2025
Maintains: Overweight
Price Target: $80 → $91
Current: $65.77
Upside: +38.36%
Cabaletta Bio
Apr 1, 2025
Maintains: Equal-Weight
Price Target: $6 → $3
Current: $1.63
Upside: +84.05%
Mar 21, 2025
Maintains: Equal-Weight
Price Target: $11 → $10
Current: $4.87
Upside: +105.34%
Mar 12, 2025
Maintains: Equal-Weight
Price Target: $16 → $15
Current: $1.44
Upside: +941.67%
Feb 28, 2025
Maintains: Overweight
Price Target: $723 → $741
Current: $543.48
Upside: +36.34%
Feb 24, 2025
Downgrades: Equal-Weight
Price Target: $36
Current: $46.15
Upside: -21.99%
Feb 13, 2025
Maintains: Overweight
Price Target: $40 → $51
Current: $23.75
Upside: +114.74%
Jan 30, 2025
Maintains: Equal-Weight
Price Target: $8 → $6
Current: $1.26
Upside: +376.19%
Dec 19, 2024
Maintains: Equal-Weight
Price Target: $12 → $14
Current: $13.04
Upside: +7.36%
Dec 19, 2024
Maintains: Equal-Weight
Price Target: $11 → $9
Current: $4.58
Upside: +96.51%
Dec 19, 2024
Maintains: Overweight
Price Target: $47 → $45
Current: $16.95
Upside: +165.49%
Dec 19, 2024
Upgrades: Overweight
Price Target: $8 → $12
Current: $1.48
Upside: +710.81%
Dec 19, 2024
Downgrades: Equal-Weight
Price Target: $27
Current: $15.67
Upside: +72.30%
Nov 15, 2024
Maintains: Overweight
Price Target: $44 → $24
Current: $2.81
Upside: +754.09%
Sep 17, 2024
Maintains: Overweight
Price Target: $264 → $289
Current: $174.18
Upside: +65.92%
Aug 12, 2024
Maintains: Overweight
Price Target: $16 → $11
Current: $2.08
Upside: +428.85%
Aug 12, 2024
Maintains: Equal-Weight
Price Target: $35 → $37
Current: $22.00
Upside: +68.18%
May 15, 2024
Maintains: Overweight
Price Target: $12 → $10
Current: $2.89
Upside: +246.02%
May 5, 2021
Downgrades: Hold
Price Target: $37 → $20
Current: $1.17
Upside: +1,609.40%
Aug 4, 2020
Initiates: Buy
Price Target: $18
Current: $3.01
Upside: +498.01%
Jul 23, 2020
Upgrades: Buy
Price Target: n/a
Current: $3.87
Upside: -
Jul 10, 2020
Downgrades: Hold
Price Target: $298 → $193
Current: $28.83
Upside: +569.44%
Apr 15, 2020
Reiterates: Buy
Price Target: $61 → $41
Current: $82.14
Upside: -50.09%
Mar 31, 2020
Maintains: Hold
Price Target: $480 → $160
Current: $16.73
Upside: +856.37%
Mar 17, 2020
Downgrades: Hold
Price Target: $180 → $60
Current: $11.60
Upside: +417.24%
Dec 11, 2018
Downgrades: Perform
Price Target: $29
Current: $4.97
Upside: +483.50%
Jun 22, 2018
Maintains: Outperform
Price Target: $34 → $50
Current: $2.20
Upside: +2,172.73%
Nov 15, 2017
Maintains: Outperform
Price Target: $32 → $51
Current: $13.58
Upside: +275.55%
Sep 7, 2017
Initiates: Outperform
Price Target: $88
Current: $27.20
Upside: +223.53%
Sep 7, 2017
Initiates: Market Perform
Price Target: n/a
Current: $23.22
Upside: -
Aug 3, 2017
Downgrades: Perform
Price Target: n/a
Current: $17.01
Upside: -